Franklin Resources Inc. Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)

Franklin Resources Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) by 3.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 958,037 shares of the biotechnology company’s stock after acquiring an additional 36,356 shares during the period. Franklin Resources Inc. owned about 1.68% of Ascendis Pharma A/S worth $89,059,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ASND. US Bancorp DE boosted its holdings in shares of Ascendis Pharma A/S by 58.2% in the second quarter. US Bancorp DE now owns 970 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 357 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Ascendis Pharma A/S by 17.8% in the first quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 142 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Ascendis Pharma A/S by 3,069.7% in the first quarter. Captrust Financial Advisors now owns 1,046 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,013 shares in the last quarter. Tobam boosted its holdings in shares of Ascendis Pharma A/S by 550.7% in the second quarter. Tobam now owns 1,438 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 1,217 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its holdings in shares of Ascendis Pharma A/S by 7.2% in the first quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock valued at $236,000 after acquiring an additional 135 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $118.84 on Thursday. The company has a current ratio of 7.56, a quick ratio of 6.83 and a debt-to-equity ratio of 1.18. The stock has a market cap of $6.78 billion, a P/E ratio of -12.90 and a beta of 0.55. The company has a 50-day moving average of $111.38 and a two-hundred day moving average of $97.60. Ascendis Pharma A/S has a 12-month low of $61.58 and a 12-month high of $148.74.

Analyst Ratings Changes

ASND has been the topic of several analyst reports. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $172.00 to $169.00 and set an “overweight” rating on the stock in a report on Monday, November 7th. SVB Leerink decreased their price objective on shares of Ascendis Pharma A/S from $168.00 to $148.00 and set an “outperform” rating on the stock in a report on Monday, November 14th. The Goldman Sachs Group started coverage on shares of Ascendis Pharma A/S in a report on Thursday, October 20th. They set a “buy” rating and a $174.00 price objective on the stock. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $151.00 to $164.00 and gave the stock an “outperform” rating in a report on Monday, November 14th. Finally, Berenberg Bank reissued a “buy” rating and set a $166.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $159.55.

Ascendis Pharma A/S Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Read More

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASNDGet Rating).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.